# About Sermorelin Compound: An Independent Research Digest

> Sermorelin Compound is an independent editorial project that summarizes the peer-reviewed research on sermorelin. Not a clinic, not a pharmacy, not a vendor — a cited literature digest.

An independent editorial digest of the published research on sermorelin — what the studies measured, and what the regulatory record actually says.

## What this site is

Sermorelin Compound is an independent editorial project that publishes summaries of the peer-reviewed research literature on sermorelin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site is built as a research-reference console: a place to read the GHRH(1-29) mechanism, the pediatric and aging trials, the cognition and pharmacokinetic data, and the full regulatory record one screen at a time, with every quantitative claim mapped to a numbered source.

## What 'compound' means here

The word "compound" in this domain refers to sermorelin as a research compound and to its status as a compounded preparation under the 503A framework — an editorial frame describing the molecule and its regulatory record. It is not a claim that this site compounds, prepares, or supplies anything. We hold no inventory, fill no prescriptions, and occupy no pharmacy counter. The name marks the subject we read about, not a service we offer.

Our editorial stance is deliberately literal: state the mechanism as the studies establish it, state the [sermorelin FDA approval status](/regulatory-status) exactly as the record shows it (approved, withdrawn for commercial reasons in 2008, now Category 1 under 503A), and mark the gap where anti-aging marketing outpaces the direct evidence.

## How we handle the evidence

Every figure on this site is carried back to a specific study, listed on the references page with its DOI or PubMed identifier. Where the literature is strong — the pediatric height-velocity result, the aging-study reversal of GH and IGF-1 decline, the controlled cognition trial — we say so plainly. Where it is thin or contested — long-term anti-aging safety, general weight-loss claims, single computational findings — we mark the limit rather than paper over it. The aim is a sober, accurate readout that a careful reader can verify, not a promotional page.

---

A pixel-console readout of the sermorelin record — the GHRH(1-29) mechanism and the trial figures logged to source, and the regulatory state machine (approved, withdrawn in 2008 for commercial reasons, Category 1 under 503A) read exactly as filed; no clinic behind the screen and nothing here compounded, dosed, or sold.